Journal of Experimental Medicine, Vol 182, 1345-1355, Copyright © 1995 by Rockefeller University Press

ARTICLES

A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody

RP Rother, WL Fodor, JP Springhorn, CW Birks, E Setter, MS Sandrin, SP Squinto and SA Rollins
Department of Molecular Development, Alexion Pharmaceuticals Inc., New Haven, Connecticut 06511, USA.

Type C retroviruses endogenous to various nonprimate species can infect human cells in vitro, yet the transmission of these viruses to humans is restricted. This has been attributed to direct binding of the complement component C1q to the viral envelope protein p15E, which leads to classical pathway-mediated virolysis in human serum. Here we report a novel mechanism of complement-mediated type C retrovirus inactivation that is initiated by the binding of "natural antibody" [Ab] (anti-alpha-galactosyl Ab) to the carbohydrate epitope Gal alpha 1- 3Gal beta 1-4GlcNAc-R expressed on the retroviral envelope. Complement- mediated inactivation of amphotropic retroviral particles was found to be restricted to human and other Old World primate sera, which parallels the presence of anti-alpha-galactosyl natural Ab. Blockade or depletion of anti-alpha-galactosyl Ab in human serum prevented inactivation of both amphotropic and ecotropic murine retroviruses. Similarly, retrovirus was not killed by New World primate serum except in the presence of exogenous anti-alpha-galactosyl Ab. Enzyme-linked immunosorbent assays revealed that the alpha-galactosyl epitope was expressed on the surface of amphotropic and ecotropic retroviruses, and Western blot analysis further localized this epitope to the retroviral envelope glycoprotein gp70. Finally, down-regulation of this epitope on the surface of murine retroviral particle producer cells rendered them, as well as the particles liberated from these cells, resistant to inactivation by human serum complement. Our data suggest that anti- alpha-galactosyl Ab may provide a barrier for the horizontal transmission of retrovirus from species that express the alpha- galactosyl epitope to humans and to other Old World primates. Further, these data provide a mechanism for the generation of complement- resistant retroviral vectors for in vivo gene therapy applications where exposure to human complement is unavoidable.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

• Xu, Z., Tian, J., Smith, J. S., Byrnes, A. P. (2008). Clearance of Adenovirus by Kupffer Cells Is Mediated by Scavenger Receptors, Natural Antibodies, and Complement. J. Virol. 82: 11705-11713 [Abstract] [Full Text]  
• Turcot-Dubois, A.-L., Le Moullac-Vaidye, B., Despiau, S., Roubinet, F., Bovin, N., Le Pendu, J., Blancher, A. (2007). Long-term evolution of the CAZY glycosyltransferase 6 (ABO) gene family from fishes to mammals--a birth-and-death evolution model. Glycobiology 17: 516-528 [Abstract] [Full Text]  
• KOLOKOLTSOV, A. A., WANG, E., COLPITTS, T. M., WEAVER, S. C., DAVEY, R. A. (2006). Pseudotyped viruses permit rapid detection of neutralizing antibodies in human and equine serum against venezuelan equine encephalitis virus.. Am J Trop Med Hyg 75: 702-709 [Abstract] [Full Text]  
• Narang, A. S., Mahato, R. I. (2006). Biological and biomaterial approaches for improved islet transplantation.. Pharmacol. Rev. 58: 194-243 [Abstract] [Full Text]  
• Magre, S., Takeuchi, Y., Langford, G., Richards, A., Patience, C., Weiss, R. (2004). Reduced Sensitivity to Human Serum Inactivation of Enveloped Viruses Produced by Pig Cells Transgenic for Human CD55 or Deficient for the Galactosyl-{alpha}(1-3) Galactosyl Epitope. J. Virol. 78: 5812-5819 [Abstract] [Full Text]  
• Croyle, M. A., Callahan, S. M., Auricchio, A., Schumer, G., Linse, K. D., Wilson, J. M., Brunner, L. J., Kobinger, G. P. (2004). PEGylation of a Vesicular Stomatitis Virus G Pseudotyped Lentivirus Vector Prevents Inactivation in Serum. J. Virol. 78: 912-921 [Abstract] [Full Text]  
• Dekker, S., Toussaint, W., Panayotou, G., de Wit, T., Visser, P., Grosveld, F., Drabek, D. (2003). Intracellularly Expressed Single-Domain Antibody against p15 Matrix Protein Prevents the Production of Porcine Retroviruses. J. Virol. 77: 12132-12139 [Abstract] [Full Text]  
• Unfer, R. C., Hellrung, D., Link, C. J. Jr. (2003). Immunity to the {alpha}(1,3)Galactosyl Epitope Provides Protection in Mice Challenged with Colon Cancer Cells Expressing {alpha}(1,3)Galactosyl-transferase: A Novel Suicide Gene for Cancer Gene Therapy. Cancer Res. 63: 987-993 [Abstract] [Full Text]  
• Tseng, J.-C., Levin, B., Hirano, T., Yee, H., Pampeno, C., Meruelo, D. (2002). In Vivo Antitumor Activity of Sindbis Viral Vectors. JNCI J Natl Cancer Inst 94: 1790-1802 [Abstract] [Full Text]  
• Sandrin, V., Boson, B., Salmon, P., Gay, W., Negre, D., Le Grand, R., Trono, D., Cosset, F.-L. (2002). Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates. Blood 100: 823-832 [Abstract] [Full Text]  
• Preece, A. F., Strahan, K. M., Devitt, J., Yamamoto, F.-i., Gustafsson, K. (2002). Expression of ABO or related antigenic carbohydrates on viral envelopes leads to neutralization in the presence of serum containing specific natural antibodies and complement. Blood 99: 2477-2482 [Abstract] [Full Text]  
• Takefman, D. M., Spear, G. T., Saifuddin, M., Wilson, C. A. (2002). Human CD59 Incorporation into Porcine Endogenous Retrovirus Particles: Implications for the Use of Transgenic Pigs for Xenotransplantation. J. Virol. 76: 1999-2002 [Abstract] [Full Text]  
• Friedman, H. M., Wang, L., Pangburn, M. K., Lambris, J. D., Lubinski, J. (2000). Novel Mechanism of Antibody-Independent Complement Neutralization of Herpes Simplex Virus Type 1. J. Immunol. 165: 4528-4536 [Abstract] [Full Text]  
• Ni, Y., Powell, R., Turner, D. D., Tizard, I. (2000). Specificity and Prevalence of Natural Bovine Anti-Alpha Galactosyl (Galalpha 1-6Glc or Galalpha 1-6Gal) Antibodies. CVI 7: 490-496 [Abstract] [Full Text]  
• Link, C. J., Seregina, T., Traynor, A., Burt, R. K. (2000). Cellular Suicide Therapy of Malignant Disease. The Oncologist 5: 68-74 [Abstract] [Full Text]  
• Sena-Esteves, M., Saeki, Y., Camp, S. M., Chiocca, E. A., Breakefield, X. O. (1999). Single-Step Conversion of Cells to Retrovirus Vector Producers with Herpes Simplex Virus-Epstein-Barr Virus Hybrid Amplicons. J. Virol. 73: 10426-10439 [Abstract] [Full Text]  
• Meneses, P. I., Abrey, L. E., Hajjar, K. A., Gultekin, S. H., Duvoisin, R. M., Berns, K. I., Rosenfeld, M. R. (1999). Simplified Production of a Recombinant Human Angiostatin Derivative That Suppresses Intracerebral Glial Tumor Growth. Clin. Cancer Res. 5: 3689-3694 [Abstract] [Full Text]  
• DePolo, N. J., Harkleroad, C. E., Bodner, M., Watt, A. T., Anderson, C. G., Greengard, J. S., Murthy, K. K., Dubensky, T. W. Jr., Jolly, D. J. (1999). The Resistance of Retroviral Vectors Produced from Human Cells to Serum Inactivation In Vivo and In Vitro Is Primate Species Dependent. J. Virol. 73: 6708-6714 [Abstract] [Full Text]  
• LaTemple, D. C., Abrams, J. T., Zhang, S. Y., Galili, U. (1999). Increased Immunogenicity of Tumor Vaccines Complexed with Anti-Gal: Studies in Knockout Mice for {{alpha}}1,3Galactosyltransferase. Cancer Res. 59: 3417-3423 [Abstract] [Full Text]  
• Ikeda, F., Haraguchi, Y., Jinno, A., Iino, Y., Morishita, Y., Shiraki, H., Hoshino, H. (1998). Human Complement Component C1q Inhibits the Infectivity of Cell-Free HTLV-I. J. Immunol. 161: 5712-5719 [Abstract] [Full Text]  
• Welsh, R. M., O'Donnell, C. L., Reed, D. J., Rother, R. P. (1998). Evaluation of the Galalpha 1-3Gal Epitope as a Host Modification Factor Eliciting Natural Humoral Immunity to Enveloped Viruses. J. Virol. 72: 4650-4656 [Abstract] [Full Text]  
• Makrides, S. C. (1998). Therapeutic Inhibition of the Complement System. Pharmacol. Rev. 50: 59-88 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS